STOCKSCOPE

Excite Technology Services (ASX: EXT): Two Government Wins and a Cash Flow Breakthrough Could Change the Story

Danny Aad

Danny Aad

Technology & Biotechnology Specialist | StockScope

Published:26 Oct 2026
Excite Technology Services (ASX: EXT): Two Government Wins and a Cash Flow Breakthrough Could Change the Story

Excite Technology Services (ASX: EXT) is showing signs of a potentially important turnaround, with new federal government contracts arriving as the cybersecurity specialist reports its strongest quarterly operating cash flow on record. With the shares recently trading around A$0.005, the key question is whether stronger cash generation and growing government demand can turn this small-cap into a more sustainable business.

The numbers are starting to look different

  • FY26 revenue: A$21.33 million, up 74% year on year.
  • FY26 net loss: A$5.39 million, down 16% year on year.
  • September-quarter operating cash flow: A$1.33 million positive.
  • Quarterly customer receipts: A$7.20 million, up 47% on the June quarter and 71% year on year.
  • Cash at 30 September 2026: A$3.98 million.

The annual results demonstrate substantial revenue growth, while the September-quarter figures suggest the company's restructuring is beginning to improve cash generation. However, Excite remains loss-making, and stronger operating cash flow does not yet establish that it can sustain profitability.

Government contracts strengthen the growth outlook

Excite has recently secured two significant federal government opportunities.

On 20 October, its subsidiary CBIT secured a A$2.9 million contract to supply digital forensics and investigative analytics software and related services to a federal government regulator. The agreement runs for 24 months to September 2028. However, the regulator retains the right to vary the scope or volume of work or terminate the agreement under standard federal government terms.

In September, Excite also announced a A$3.2 million expansion of an existing federal government digital forensics contract, covering certified digital evidence collection, forensic software, specialised hardware and training over a further 24 months.

These awards strengthen Excite's position in a specialised market where government agencies require reliable investigative technology and digital evidence capabilities. Their multi-year terms improve revenue visibility, although delivery costs, contract margins and the timing of revenue recognition will determine their ultimate financial contribution.

Cash flow could be the real breakthrough

Excite's September-quarter update offers a more encouraging signal than revenue growth alone. Operating cash inflow reached A$1.33 million, an improvement of A$3.23 million on the June quarter. Customer receipts increased to A$7.20 million from A$4.90 million, while management reported a staff cost base 26% lower than a year earlier.

Importantly, the improvement extends beyond a single quarter. Excite generated A$1.22 million in positive operating cash flow over the six months to 30 September 2026, an improvement of approximately A$3.64 million against the corresponding prior-year period.

The result suggests the company's cost restructuring is beginning to deliver operating leverage. Higher customer receipts combined with lower staffing costs have helped the business convert its operations into cash. Nevertheless, the company will need to sustain this performance through different reporting periods before investors can conclude that the turnaround is durable.

The balance sheet also requires context. Excite ended September with A$3.98 million in cash, compared with A$466,000 at the end of June. However, the company received A$3.50 million in placement proceeds before costs during the quarter. Its stronger liquidity therefore reflects both the capital raising and the return to positive operating cash flow.

Excite provides cybersecurity, managed IT, digital forensics, incident response and specialist training services to government and enterprise customers. Its opportunity is to build broader customer relationships, increase recurring managed-services revenue and improve margins as the business grows.

Valuation and catalysts: what comes next?

At a share price of A$0.005, Excite's market capitalisation is approximately A$14 million, based on recent market data. This is modest relative to FY26 revenue of A$21.33 million, but a simple price-to-sales comparison can be misleading for a company with continuing losses and substantial software and hardware resale revenue.

The capital structure and balance sheet also deserve attention. The A$3.50 million placement strengthened liquidity but introduced additional shares, creating dilution for existing shareholders. The key question is whether improved operating performance can increase the value generated per share over time.

Management's October growth plan identifies several priorities: accelerating sales, converting advisory and assessment engagements into recurring managed services, expanding existing customer relationships, developing secure AI capabilities and strengthening technology partnerships.

The next catalysts are sustained positive operating cash flow, profitable execution of government contracts and stronger recurring revenue from cybersecurity and managed IT services. Secure AI capabilities offer another potential growth avenue, but their commercial contribution remains to be demonstrated.

Insight: Can a cash-generating quarter become a lasting turnaround?

We see the most interesting development as the combination of stronger customer receipts, a leaner cost base and expanding government relationships. Excite has made measurable progress towards its stated goal of moving from financial recovery to more consistent operating performance.

If the company can sustain positive operating cash flow while converting new contracts into profitable revenue, its financial profile could improve considerably. However, investors should distinguish between a promising operational milestone and an established turnaround. Further contract wins will matter, but margins, working capital requirements and cash generation will ultimately determine whether the business can fund its growth internally.

The verdict: a turnaround worth watching

Excite has made tangible commercial progress, and its latest cash flow result provides a credible reason to look beyond its loss-making history. We believe the opportunity lies in proving that government demand and operational restructuring can deliver sustainable profitability.

The company's financial position has improved, and the new contracts add to its forward revenue visibility. Nevertheless, the A$3.50 million placement remains an important contributor to the cash balance, while the government agreements carry delivery and contractual risks.

The key milestone is not simply another contract win, but continued positive operating cash flow supported by stronger underlying trading. The December-quarter update should help determine whether September marked the beginning of a lasting turnaround or an encouraging result that still needs to be replicated.

Danny Aad

Danny Aad

(Technology & Biotechnology Specialist | StockScope)

Danny Aad is an experienced technology executive with a distinguished career spanning more than three decades, including senior leadership positions as Chief Technology Officer (CTO) across the technology and biotechnology sectors. With extensive expertise in technology strategy, digital innovation and the evolving biotechnology landscape, Danny brings a wealth of industry knowledge and technical insight to his analysis of emerging technologies, corporate developments and investment opportunities.

DisclaimerInformation on Stockscope is general in nature and does not constitute financial product advice. It does not take into account your personal objectives, financial situation or needs. Seek independent advice from a qualified financial adviser before making an investment decision. Stockscope and its affiliates do not guarantee the accuracy or completeness of information published on this website. To the extent permitted by law, they accept no liability for any claim, loss or damage arising from its use or reliance on it. Stockscope and its associates may have commercial relationships with companies featured on this website, hold securities in those companies, or receive commissions in connection with capital raisings.

Continue Reading

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore
Market Briefings
Market Briefings

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore

Australian equities: what moved the ASX 200? Australian shares finished lower on Friday, 6 November, as the technology-led sell-off on Wall Street spread across global markets. The ASX 200...

Mark ElzayedMark Elzayed•
Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test
Biotech & Health
Biotech & Health

Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test

Epiminder Limited ASX: EPI has expanded the US market for its epilepsy monitoring technology following a significant regulatory clearance, strengthening its commercial prospects ahead of a p...

Danny AadDanny Aad•
Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?
Mining
Mining

Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?

A 38-metre gold intersection grading 2.1 grams per tonne has given Asara Resources Limited ASX: AS1 an encouraging exploration result beyond its established Massan deposit in Guinea. The dis...

Alison ElzayedAlison Elzayed•
Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?
Mining
Mining

Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?

Alvo Minerals Limited ASX: ALV has extended rare earth mineralisation approximately 2 kilometres beyond previously tested areas at its Boa Vista prospect in Brazil, strengthening the explora...

Alison ElzayedAlison Elzayed•
Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet
Mining
Mining

Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet

Avenira Limited ASX: AEV has reached a significant financing milestone, with its $48.9 million rights issue providing fresh capital to advance the Wonarah Phosphate Project in the Northern T...

Alison ElzayedAlison Elzayed•
Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?
Biotech & Health
Biotech & Health

Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?

Mayne Pharma Group Limited ASX: MYX is taking a decisive step towards becoming a US-focused pharmaceutical company, agreeing to sell its international operations for $55.5 million. The tran...

Danny AadDanny Aad•
Loading more stories...